aod 9604 and retatrutide retatrutide: evidence, risks, and UK legal status AOD-9604 laboratory research Archives -
Description
Peter Attia have warned of significant muscle loss and the oft-mentioned "Ozempic face," in which the drastic weight loss can lead to sagging and other facial changes
Research is still emerging on long-term health impacts and potential side effects
Important topics include: Potential drug interactions between GLP-1 medications and DMARDs Monitoring strategies for both conditions Whether weight loss might improve RA symptoms or treatment response Cardiovascular risk reduction strategies Safety considerations including contraindications (personal/family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2) Patients should not discontinue or modify DMARD therapy based on unproven theories about GLP-1 medications treating RA
Many patients describe this as "silencing the food noise" that constant preoccupation with food
What is the process of taking a GLP-1 nutrition support product
GLP-1 was reported to inhibit pancreatic beta-cell apoptosis and stimulate the proliferation and differentiation of insulin-secreting beta-cells
